Risk factor
Strong trading liquidity
Profitability factor
Decent dividends
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of 4523.T is 5135 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell